Palisade Bio (NASDAQ:PALI) Stock Continues to Move Lower: Time to Buy?
Late-stage biopharmaceutical company focused on advancing therapies helping patients with acute and chronic gastrointestinal complications, Palisade Bio (NASDAQ:PALI) on July 29, 2021, announced entering into exclusive license with the Regents of the University of California. This will facilitate expansion of the technology to detect enzymatic protease activity in human clinical samples. In combination with 2020 license from University of California, the firm gets worldwide exclusive license for patent rights covering…